These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 27544929)

  • 1. Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer.
    Tate SC; Andre V; Enas N; Ribba B; Gueorguieva I
    Eur J Cancer; 2016 Oct; 66():95-103. PubMed ID: 27544929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments.
    Del Mastro L; Fabi A; Mansutti M; De Laurentiis M; Durando A; Merlo DF; Bruzzi P; La Torre I; Ceccarelli M; Kazeem G; Marchi P; Boy D; Venturini M; De Placido S; Cognetti F
    BMC Cancer; 2013 Mar; 13():164. PubMed ID: 23537313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of gemcitabine activity in advanced breast cancer.
    Smith IE
    Semin Oncol; 2006 Jun; 33(3 Suppl 9):S19-23. PubMed ID: 16797378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
    Cinieri S; Chan A; Altundag K; Vandebroek A; Tubiana-Mathieu N; Barnadas A; Dodyk P; Lazzarelli S; Botha M; Rauch D; Villanova G; Coskun U
    Clin Breast Cancer; 2017 Apr; 17(2):91-99.e1. PubMed ID: 27756583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: towards optimization of association and schedule.
    Metro G; Fabi A; Russillo M; Papaldo P; De Laurentiis M; Ferretti G; Pellegrini D; Nuzzo C; Graziano V; Vici P; Introna M; Felici A; Cognetti F; Carlini P
    Anticancer Res; 2008; 28(2B):1245-58. PubMed ID: 18505062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.
    Mavroudis D; Malamos N; Alexopoulos A; Kourousis C; Agelaki S; Sarra E; Potamianou A; Kosmas C; Rigatos G; Giannakakis T; Kalbakis K; Apostolaki F; Vlachonicolis J; Kakolyris S; Samonis G; Georgoulias V
    Ann Oncol; 1999 Feb; 10(2):211-5. PubMed ID: 10093691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine and taxanes in metastatic breast cancer.
    Amadori D; Cecconetto L
    Ann Oncol; 2006 May; 17 Suppl 5():v173-6. PubMed ID: 16807451
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
    Park YH; Im SA; Kim SB; Sohn JH; Lee KS; Chae YS; Lee KH; Kim JH; Im YH; Kim JY; Kim TY; Lee KH; Ahn JH; Kim GM; Park IH; Lee SJ; Han HS; Kim SH; Jung KH;
    Eur J Cancer; 2017 Nov; 86():385-393. PubMed ID: 29100193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine for the treatment of metastatic breast cancer.
    Jones J; Takeda A; Tan SC; Cooper K; Loveman E; Clegg A
    Health Technol Assess; 2009 Sep; 13 Suppl 2():1-7. PubMed ID: 19804683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine combined with docetaxel in metastatic breast cancer.
    Fumoleau P
    Semin Oncol; 2003 Apr; 30(2 Suppl 3):15-8. PubMed ID: 12722020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer.
    Rodgers M; Soares M; Epstein D; Yang H; Fox D; Eastwood A
    Health Technol Assess; 2011 May; 15 Suppl 1():1-12. PubMed ID: 21609648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taxane-based mono- or combination therapy for managing metastatic breast cancer (MBC) in routine practice: a multinational prospective observational study.
    Gümüş M; Davidson N; Bauknecht T; Soldatenkova V; Benhadji KA
    Curr Med Res Opin; 2012 Mar; 28(3):401-13. PubMed ID: 22181343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment for anthracycline-pretreated metastatic breast cancer.
    O'Shaughnessy J; Twelves C; Aapro M
    Oncologist; 2002; 7 Suppl 6():4-12. PubMed ID: 12454314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly docetaxel with or without gemcitabine as second-line chemotherapy in paclitaxel-pretreated patients with metastatic breast cancer: a randomized phase II study conducted by the Hellenic Co-Operative Oncology Group.
    Papadimitriou CA; Kalofonos H; Zagouri F; Papakostas P; Bozas G; Makatsoris T; Dimopoulos MA; Fountzilas G
    Oncology; 2009; 77(3-4):212-6. PubMed ID: 19729979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine combination chemotherapy in metastatic breast cancer: phase II experience.
    O'Shaughnessy J
    Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):15-21. PubMed ID: 14768400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine in the management of metastatic breast cancer: a systematic review.
    Dent S; Messersmith H; Trudeau M
    Breast Cancer Res Treat; 2008 Apr; 108(3):319-31. PubMed ID: 17530427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer.
    Seidman AD; Chan S; Wang J; Zhu C; Xu C; Xu B
    Oncologist; 2014 May; 19(5):443-52. PubMed ID: 24705980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study.
    Brugnatelli S; Danova M; De Bella MT; Vaglica M; Manuguerra G; Riccardi A; Palmeri S
    Oncology; 2002; 62(1):33-8. PubMed ID: 11810041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation.
    Takeda AL; Jones J; Loveman E; Tan SC; Clegg AJ
    Health Technol Assess; 2007 May; 11(19):iii, ix-xi, 1-62. PubMed ID: 17462169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
    O'Shaughnessy J; Miles D; Vukelja S; Moiseyenko V; Ayoub JP; Cervantes G; Fumoleau P; Jones S; Lui WY; Mauriac L; Twelves C; Van Hazel G; Verma S; Leonard R
    J Clin Oncol; 2002 Jun; 20(12):2812-23. PubMed ID: 12065558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.